194 related articles for article (PubMed ID: 38564022)
1. Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy.
Chen JY; Lin PY; Hong WZ; Yang PC; Chiang SF; Chang HY; Ke TW; Liang JA; Chen WT; Chao KSC; Huang KC
Cancer Immunol Immunother; 2024 Apr; 73(5):92. PubMed ID: 38564022
[TBL] [Abstract][Full Text] [Related]
2. Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.
Liu C; Wang X; Qin W; Tu J; Li C; Zhao W; Ma L; Liu B; Qiu H; Yuan X
Cancer Commun (Lond); 2023 Apr; 43(4):435-454. PubMed ID: 36855844
[TBL] [Abstract][Full Text] [Related]
3. Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy.
Huang KC; Chiang SF; Yang PC; Ke TW; Chen TW; Hu CH; Huang YW; Chang HY; Chen WT; Chao KSC
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799527
[TBL] [Abstract][Full Text] [Related]
4. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of radiation-induced DNA damage and inhibition of its repair by a novel camptothecin analog.
Huang G; Wang H; Yang LX
Anticancer Res; 2010 Mar; 30(3):937-44. PubMed ID: 20393017
[TBL] [Abstract][Full Text] [Related]
6. TLC388 Induces DNA Damage and G2 Phase Cell Cycle Arrest in Human Non-Small Cell Lung Cancer Cells.
Wu KM; Chi CW; Lai JC; Chen YJ; Kou YR
Cancer Control; 2020; 27(1):1073274819897975. PubMed ID: 32281394
[TBL] [Abstract][Full Text] [Related]
7. Combination of Anti-PD-1 and Electroacupuncture Induces a Potent Antitumor Immune Response in Microsatellite-Stable Colorectal Cancer.
Wang Y; Liu F; Du X; Shi J; Yu R; Li S; Na R; Zhao Y; Zhou M; Guo Y; Cheng L; Wang G; Zheng T
Cancer Immunol Res; 2024 Jan; 12(1):26-35. PubMed ID: 37956404
[TBL] [Abstract][Full Text] [Related]
8. Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade.
Huang KC; Chiang SF; Chang HY; Chen WT; Yang PC; Chen TW; Liang JA; Shiau AC; Ke TW; Clifford Chao KS
Cell Death Dis; 2022 Jul; 13(7):610. PubMed ID: 35835756
[TBL] [Abstract][Full Text] [Related]
9. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
Lee JM; Shin KS; Koh CH; Song B; Jeon I; Park MH; Kim BS; Chung Y; Kang CY
Cancer Lett; 2021 Nov; 520():38-47. PubMed ID: 34224797
[TBL] [Abstract][Full Text] [Related]
11. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
12. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
13. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer.
Chung SY; Chang YC; Hsu DS; Hung YC; Lu ML; Hung YP; Chiang NJ; Yeh CN; Hsiao M; Soong J; Su Y; Chen MH
Neoplasia; 2023 Jan; 35():100856. PubMed ID: 36442297
[TBL] [Abstract][Full Text] [Related]
14. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
15. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer.
Quan Y; He J; Zou Q; Zhang L; Sun Q; Huang H; Li W; Xie K; Wei F
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597850
[TBL] [Abstract][Full Text] [Related]
16. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer.
Kim CW; Chon HJ; Kim C
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638390
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer.
Wu C; Shao Y; Gu W
Clin Transl Oncol; 2023 Jul; 25(7):1916-1928. PubMed ID: 36717514
[TBL] [Abstract][Full Text] [Related]
18. A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells.
Tan X; Fang P; Li K; You M; Cao Y; Xu H; Zhu X; Wang L; Wei X; Wen H; Li W; Shi L; Sun X; Yu D; Zhu H; Wang Z; Liu D; Shen H; Zhou W; An M
MAbs; 2023; 15(1):2220466. PubMed ID: 37314961
[TBL] [Abstract][Full Text] [Related]
19. SAMHD1 silencing cooperates with radiotherapy to enhance anti-tumor immunity through IFI16-STING pathway in lung adenocarcinoma.
Li Y; Gao Y; Jiang X; Cheng Y; Zhang J; Xu L; Liu X; Huang Z; Xie C; Gong Y
J Transl Med; 2022 Dec; 20(1):628. PubMed ID: 36578072
[TBL] [Abstract][Full Text] [Related]
20. Synthetic enforcement of STING signaling in cancer cells appropriates the immune microenvironment for checkpoint inhibitor therapy.
Vornholz L; Isay SE; Kurgyis Z; Strobl DC; Loll P; Mosa MH; Luecken MD; Sterr M; Lickert H; Winter C; Greten FR; Farin HF; Theis FJ; Ruland J
Sci Adv; 2023 Mar; 9(11):eadd8564. PubMed ID: 36921054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
